Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal Pharmaceuticals NASDAQ: MDGL said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH therapy and prepared for several potential clinical catalysts.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
Madrigal Pharmaceuticals NASDAQ: MDGL reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients receiving its treatment for metabolic dysfunction-associated steatohepatitis, or MASH.
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $1.99 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to a loss of $1.9 per share a year ago.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $3.25 per share versus the Zacks Consensus Estimate of a loss of $3.61. This compares to a loss of $3.32 per share a year ago.
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
Madrigal Pharmaceuticals, Inc. receives a Sell rating, citing high valuation and intensifying MASH competition despite Rezdiffra's initial commercial success. Rezdiffra achieved $958.4m in 2025 sales with ~36,250 patients, but MDGL profitability remains elusive as operating expenses outpace revenue growth. SG&A and R&D costs are expected to rise in 2026, while no specific guidance has been provided, and consensus sees potential Q1 revenue softness.
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
